Vorinostat

Generic Name: Vorinostat

Brand Names: Zolinza

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₂₀N_₂O_₃

CAS Number: 149647-78-9

Unique Ingredient Identifier: 58IFB293JI

Background: Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...

Indication: 用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。

Associated Conditions: Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma

Associated Therapies: -

Clinical Trials

Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

Phase 1

Completed

Conditions: Recurrent Renal Cell Cancer
Stage IV Renal Cell Cancer
Clear Cell Renal Cell Carcinoma
Stage III Renal Cell Cancer

Interventions: Drug: vorinostat
Drug: bevacizumab

First Posted Date: 2006-05-11

Last Posted Date: 2016-01-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00324870

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Peninsula Oncology and Hematology PA, Salisbury, Maryland, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: bortezomib
Drug: vorinostat
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2006-04-03

Last Posted Date: 2013-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00310024

Locations: 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States

Vorinostat in Treating Patients With Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Recurrent Adult Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia
Adult Acute Erythroid Leukemia (M6)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Refractory Cytopenia With Multilineage Dysplasia

Interventions: Drug: vorinostat

First Posted Date: 2006-03-22

Last Posted Date: 2014-05-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00305773

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: vorinostat
Drug: paclitaxel
Drug: carboplatin
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2006-02-07

Last Posted Date: 2013-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00287937

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia

Phase 1

Completed

Conditions: Blastic Phase Chronic Myelogenous Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Refractory Anemia With Excess Blasts
Relapsing Chronic Myelogenous Leukemia
Untreated Adult Acute Lymphoblastic Leukemia
Untreated Adult Acute Myeloid Leukemia

Interventions: Drug: alvocidib
Drug: vorinostat

First Posted Date: 2006-01-18

Last Posted Date: 2013-04-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00278330

Locations: 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

Vorinostat in Treating Patients With Kidney Cancer

Phase 2

Completed

Conditions: Recurrent Renal Cell Carcinoma
Stage IV Renal Cell Cancer

Interventions: Drug: Vorinostat

First Posted Date: 2006-01-18

Last Posted Date: 2017-11-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT00278395

Locations: 🇺🇸
Institute for Drug Development, San Antonio, Texas, United States
🇺🇸
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States

Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia

Phase 1

Completed

Conditions: Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Stage III Adult Immunoblastic Large Cell Lymphoma
Stage III Grade 2 Follicular Lymphoma
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Recurrent Adult Acute Myeloid Leukemia
Recurrent Adult Burkitt Lymphoma

Interventions: Drug: vorinostat
Drug: decitabine

First Posted Date: 2006-01-11

Last Posted Date: 2014-08-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT00275080

Locations: 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada
🇨🇦
Chedoke-McMaster Hospitals, Hamilton, Ontario, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

and more 1 locations

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Phase 1

Active, not recruiting

Conditions: Adult Giant Cell Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Neoplasm
Adult Anaplastic Astrocytoma
Adult Mixed Glioma
Adult Anaplastic Oligodendroglioma
Adult Glioblastoma

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Temozolomide
Drug: Vorinostat

First Posted Date: 2005-12-22

Last Posted Date: 2024-08-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 83

Registration Number: NCT00268385

Locations: 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
UCSF Medical Center-Mount Zion, San Francisco, California, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 14 locations

Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer

Phase 2

Completed

Conditions: Stage II Breast Cancer
Stage III Breast Cancer
Breast Cancer
Stage I Breast Cancer

Interventions: Drug: vorinostat
Other: conventional surgery

First Posted Date: 2005-12-07

Last Posted Date: 2020-02-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT00262834

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer
Male Breast Cancer
Recurrent Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: vorinostat
Drug: trastuzumab

First Posted Date: 2005-11-24

Last Posted Date: 2014-06-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 16

Registration Number: NCT00258349

Locations: 🇺🇸
Siouxland Hematology Oncology Associates, Sioux City, Iowa, United States
🇺🇸
Iowa Methodist Medical Center, Des Moines, Iowa, United States
🇺🇸
Woodwinds Health Campus, Woodbury, Minnesota, United States

and more 22 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy